中國金茂(00817.HK)累計簽約銷售達1482.2億元 同比增逾三成
格隆匯12月4日丨中國金茂(00817.HK)發佈公告,2019年11月份,集團取得簽約銷售金額人民幣122.2263億元,簽約銷售建築面積約63.62萬平方米。
截至2019年11月30日止11個月,集團累計取得簽約銷售金額共計人民幣1482.1779億元(其中包含(如有)長沙梅溪湖國際新城項目、南京青龍山國際生態新城項目及寧波生命科學城項目的成交銷售金額),同比增長30.23%;以及累計簽約銷售建築面積約680.2萬平方米。
此外,於2019年11月30日,集團已錄得已認購(未簽約)物業銷售金額共計人民幣70.9348億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.